secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xenon Pharmaceuticals Inc. (XENE)
CIK:        0001582313
Form:       8-K
Filed at:   2022-05-10T23:59:59+00:00
Accession:  0001564590-22-019282
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xenon Q1 net loss $19.7M; XEN1101 Phase 3 on track for H2 2022
--------------------------------------------------------------

- Net loss $19.7M vs $15.8M YoY; revenue $8.8M, up from $4.4M on Neurocrine milestone.
- Cash $537.9M, sufficient to fund operations into at least 2024.
- XEN1101 Phase 2b met primary endpoint; FDA End-of-Phase 2 meeting Q2 2022; Phase 3 start H2 2022.
- Phase 2 X-NOVA for MDD initiated; topline results expected in 2023.
- XEN496 Phase 3 EPIK in KCNQ2-DEE ongoing; completion anticipated in 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1582313/000156459022019282/0001564590-22-019282-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1582313/000156459022019282/xene-8k_20220510.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-019282

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer